1
|
Kaczor A, Knutelska J, Kucwaj-Brysz K, Zygmunt M, Żesławska E, Siwek A, Bednarski M, Podlewska S, Jastrzębska-Więsek M, Nitek W, Sapa J, Handzlik J. The Subtype Selectivity in Search of Potent Hypotensive Agents among 5,5-Dimethylhydantoin Derived α 1-Adrenoceptors Antagonists. Int J Mol Sci 2023; 24:16609. [PMID: 38068933 PMCID: PMC10706087 DOI: 10.3390/ijms242316609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 11/18/2023] [Accepted: 11/19/2023] [Indexed: 12/18/2023] Open
Abstract
In order to find new hypotensive drugs possessing higher activity and better selectivity, a new series of fifteen 5,5-dimethylhydantoin derivatives (1-15) was designed. Three-step syntheses, consisting of N-alkylations using standard procedures as well as microwaves, were carried out. Crystal structures were determined for compounds 7-9. All of the synthesized 5,5-dimethylhydantoins were tested for their affinity to α1-adrenergic receptors (α1-AR) using both in vitro and in silico methods. Most of them displayed higher affinity (Ki < 127.9 nM) to α1-adrenoceptor than urapidil in radioligand binding assay. Docking to two subtypes of adrenergic receptors, α1A and α1B, was conducted. Selected compounds were tested for their activity towards two α1-AR subtypes. All of them showed intrinsic antagonistic activity. Moreover, for two compounds (1 and 5), which possess o-methoxyphenylpiperazine fragments, strong activity (IC50 < 100 nM) was observed. Some representatives (3 and 5), which contain alkyl linker, proved selectivity towards α1A-AR, while two compounds with 2-hydroxypropyl linker (11 and 13) to α1B-AR. Finally, hypotensive activity was examined in rats. The most active compound (5) proved not only a lower effective dose than urapidil but also a stronger effect than prazosin.
Collapse
Affiliation(s)
- Aneta Kaczor
- Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.K.-B.)
| | - Joanna Knutelska
- Department of Pharmacodynamics, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland; (J.K.); (M.Z.); (M.B.); (J.S.)
| | - Katarzyna Kucwaj-Brysz
- Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.K.-B.)
| | - Małgorzata Zygmunt
- Department of Pharmacodynamics, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland; (J.K.); (M.Z.); (M.B.); (J.S.)
| | - Ewa Żesławska
- Institute of Biology and Earth Sciences, University of the National Education Commision, Podchorążych 2, 30-084 Krakow, Poland;
| | - Agata Siwek
- Department of Pharmacobiology, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland;
| | - Marek Bednarski
- Department of Pharmacodynamics, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland; (J.K.); (M.Z.); (M.B.); (J.S.)
| | - Sabina Podlewska
- Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Medicinal Chemistry, Smętna 12, 31-343 Krakow, Poland;
| | | | - Wojciech Nitek
- Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland;
| | - Jacek Sapa
- Department of Pharmacodynamics, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland; (J.K.); (M.Z.); (M.B.); (J.S.)
| | - Jadwiga Handzlik
- Department of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland; (A.K.); (K.K.-B.)
| |
Collapse
|
2
|
Wilder CDE, Pavlaki N, Dursun T, Gyimah P, Caldwell‐Dunn E, Ranieri A, Lewis HR, Curtis MJ. Facilitation of ischaemia-induced ventricular fibrillation by catecholamines is mediated by β 1 and β 2 agonism in the rat heart in vitro. Br J Pharmacol 2018; 175:1669-1690. [PMID: 29473948 PMCID: PMC5913407 DOI: 10.1111/bph.14176] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Revised: 01/26/2018] [Accepted: 02/08/2018] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND AND PURPOSE Antiarrhythmic β-blockers are used in patients at risk of myocardial ischaemia, but the survival benefit and mechanisms are unclear. We hypothesized that β-blockers do not prevent ventricular fibrillation (VF) but instead inhibit the ability of catecholamines to facilitate ischaemia-induced VF, limiting the scope of their usefulness. EXPERIMENTAL APPROACH ECGs were analysed from ischaemic Langendorff-perfused rat hearts perfused with adrenoceptor antagonists and/or exogenous catecholamines (CATs: 313 nM noradrenaline + 75 nM adrenaline) in a blinded and randomized study. Ischaemic zone (IZ) size was deliberately made small or large. KEY RESULTS In rat hearts with large IZs, ischaemia-induced VF incidence was high in controls. Atenolol, butoxamine and trimazosin did not affect VF at concentrations with β1 -, β2 - or α1 - adrenoceptor specificity and selectivity (confirmed in separate rat aortae myography experiments). In hearts with small IZs and low baseline incidence of ischaemia-induced VF, CATs, delivered to the uninvolved zone (UZ), increased ischaemia-induced VF incidence. This effect was not mimicked by atrial pacing, hence, not due to sinus tachycardia. However, the CATs-facilitated increase in ischaemia-induced VF was inhibited by atenolol and butoxamine (but not trimazosin), indicative of β1 - and β2 - but not α1 -adrenoceptor involvement (confirmed by immunoblot analysis of downstream phosphoproteins). CATs did not facilitate VF in low-flow globally ischaemic hearts, which have no UZ. CONCLUSIONS AND IMPLICATIONS Catecholamines facilitated ischaemia-induced VF when risk was low, acting via β1 - and β2 - adrenoceptors located in the UZ. There was no scope for facilitation when VF risk was high (large IZ), which may explain why β-blockers have equivocal effectiveness in humans.
Collapse
Affiliation(s)
- Catherine D E Wilder
- Cardiovascular Division, Faculty of Life Sciences and Medicine, The Rayne InstituteSt Thomas' HospitalLondonSE1 7EHUK
| | - Nikoleta Pavlaki
- Cardiovascular Division, Faculty of Life Sciences and Medicine, The Rayne InstituteSt Thomas' HospitalLondonSE1 7EHUK
| | - Tutku Dursun
- Cardiovascular Division, Faculty of Life Sciences and Medicine, The Rayne InstituteSt Thomas' HospitalLondonSE1 7EHUK
| | - Paul Gyimah
- Cardiovascular Division, Faculty of Life Sciences and Medicine, The Rayne InstituteSt Thomas' HospitalLondonSE1 7EHUK
| | - Ellice Caldwell‐Dunn
- Cardiovascular Division, Faculty of Life Sciences and Medicine, The Rayne InstituteSt Thomas' HospitalLondonSE1 7EHUK
| | - Antonella Ranieri
- Cardiovascular Division, Faculty of Life Sciences and Medicine, The Rayne InstituteSt Thomas' HospitalLondonSE1 7EHUK
| | - Hannah R Lewis
- Cardiovascular Division, Faculty of Life Sciences and Medicine, The Rayne InstituteSt Thomas' HospitalLondonSE1 7EHUK
| | - Michael J Curtis
- Cardiovascular Division, Faculty of Life Sciences and Medicine, The Rayne InstituteSt Thomas' HospitalLondonSE1 7EHUK
| |
Collapse
|
3
|
Wei F, Wang S, Lv N, Bu Y, Xie X. Characterization the affinity of α 1A adrenoreceptor by cell membrane chromatography with frontal analysis and stoichiometric displacement model. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1040:273-281. [DOI: 10.1016/j.jchromb.2016.11.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 10/26/2016] [Accepted: 11/01/2016] [Indexed: 10/20/2022]
|
4
|
Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine. Sci Rep 2015; 5:17969. [PMID: 26655634 PMCID: PMC4674695 DOI: 10.1038/srep17969] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Accepted: 11/10/2015] [Indexed: 12/19/2022] Open
Abstract
Ranolazine is a recently developed drug used for the treatment of patients with chronic stable angina. It is a selective inhibitor of the persistent cardiac Na+ current (INa), and is known to reduce the Na+-dependent Ca2+ overload that occurs in cardiomyocytes during ischemia. Vascular effects of ranolazine, such as vasorelaxation,have been reported and may involve multiple pathways. As voltage-gated Na+ channels (Nav) present in arteries play a role in contraction, we hypothesized that ranolazine could target these channels. We studied the effects of ranolazine in vitro on cultured aortic smooth muscle cells (SMC) and ex vivo on rat aortas in conditions known to specifically activate or promote INa. We observed that in the presence of the Nav channel agonist veratridine, ranolazine inhibited INa and intracellular Ca2+ calcium increase in SMC, and arterial vasoconstriction. In arterial SMC, ranolazine inhibited the activity of tetrodotoxin-sensitive voltage-gated Nav channels and thus antagonized contraction promoted by low KCl depolarization. Furthermore, the vasorelaxant effects of ranolazine, also observed in human arteries and independent of the endothelium, involved antagonization of the α1-adrenergic receptor. Combined α1-adrenergic antagonization and inhibition of SMCs Nav channels could be involved in the vascular effects of ranolazine.
Collapse
|
5
|
Innervation of the arterial wall and its modification in atherosclerosis. Auton Neurosci 2015; 193:7-11. [DOI: 10.1016/j.autneu.2015.06.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2015] [Revised: 05/21/2015] [Accepted: 06/17/2015] [Indexed: 01/11/2023]
|
6
|
Ma W, Ackermann L. Cobalt(II)-Catalyzed Oxidative C–H Alkenylations: Regio- and Site-Selective Access to Isoindolin-1-one. ACS Catal 2015. [DOI: 10.1021/acscatal.5b00322] [Citation(s) in RCA: 158] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Wenbo Ma
- Institut
für Organische
und Biomolekulare Chemie, Georg-August-Universität, Tammannstraße 2, 37077 Göttingen, Germany
| | - Lutz Ackermann
- Institut
für Organische
und Biomolekulare Chemie, Georg-August-Universität, Tammannstraße 2, 37077 Göttingen, Germany
| |
Collapse
|
7
|
Zhou M, Daubresse M, Stafford RS, Alexander GC. National trends in the ambulatory treatment of hypertension in the United States, 1997-2012. PLoS One 2015; 10:e0119292. [PMID: 25738503 PMCID: PMC4349596 DOI: 10.1371/journal.pone.0119292] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Accepted: 01/29/2015] [Indexed: 11/18/2022] Open
Abstract
Importance Hypertension is common and costly. Over the past decade, new antihypertensive therapies have been developed, several have lost patent protection and additional evidence regarding the safety and effectiveness of these agents has accrued. Objective To examine trends in the use of antihypertensive therapies in the United States between 1997 and 2012. Design, Setting and Participants We used nationally representative audit data from the IMS Health National Disease and Therapeutic Index to examine the ambulatory pharmacologic treatment of hypertension. Outcome Measures Our primary unit of analysis was a visit where hypertension was a reported diagnosis and treated with a pharmacotherapy (treatment visit). We restricted analyses to the use of six therapeutic classes of antihypertensive medications among individuals 18 years or older. Results Annual hypertension treatment visits increased from 56.9 million treatment visits (95% confidence intervals [CI], 53.9–59.8) in 1997 to 83.3 million visits (CI 79.2–87.3) in 2008, then declined steadily to 70.9 million visits (CI 66.7–75.0) by 2012. Angiotensin receptor blocker utilization increased substantially from 3% of treatment visits in 1997 to 18% by 2012, whereas calcium channel blocker use decreased from 27% to 18% of visits. Rates of diuretic and beta-blocker use remained stable and represented 24%–30% and 14–16% of visits, respectively. Use of direct renin inhibitor accounted for fewer than 2% of annual visits. The proportion of visits treated using fixed-dose combination therapies increased from 28% to 37% of visits. Conclusions Several important changes have occurred in the landscape of antihypertensive treatment in the United States during the past decade. Despite their novel mechanism of action, the adoption rate of direct renin inhibitors remains low.
Collapse
Affiliation(s)
- Meijia Zhou
- Department of Epidemiology, Bloomberg School of Public Health, Baltimore, Maryland, United States of America
- Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
| | - Matthew Daubresse
- Department of Epidemiology, Bloomberg School of Public Health, Baltimore, Maryland, United States of America
- Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
| | - Randall S. Stafford
- Program on Prevention Outcomes and Practices, Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California, United States of America
| | - G. Caleb Alexander
- Department of Epidemiology, Bloomberg School of Public Health, Baltimore, Maryland, United States of America
- Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
- Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland, United States of America
- * E-mail:
| |
Collapse
|
8
|
|
9
|
Sobotka PA, Krum H, Böhm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 2012; 14:285-92. [PMID: 22392370 DOI: 10.1007/s11886-012-0258-x] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The heart and kidney interact in terms of hemodynamics and neurohumoral regulatory mechanisms, and this helps to maintain circulatory homeostasis under normal conditions. However, the normal regulatory mechanisms become inappropriate in the setting of congestive heart failure (CHF), and significant renal dysfunction often develops in CHF patients. Activation of renal sympathetic efferent nerves causes renin release, sodium and water retention, and reduced renal blood flow, all hallmarks of the renal manifestations of CHF. An increase in plasma levels of angiotensin II that is mediated in part by renal sympathetic activation has an effect on the central nervous system to further increase global sympathetic tone. Renal sympathetic activity can be assessed clinically by renal norepinephrine spillover, and an increase in renal norepinephrine spillover in CHF predicts reduced survival. In addition to efferent sympathetic activation, activation of renal sensory nerves in CHF may cause a reflex increase in sympathetic tone that contributes to elevated peripheral vascular resistance and vascular remodeling as well as left ventricular remodeling and dysfunction. In animal models of heart failure, surgical renal denervation has been shown to improve both renal and ventricular function. Although surgical renal denervation has long been known to lower blood pressure and improve survival in patients with hypertension, the invasive nature of this approach and its associated complications has limited its appeal. However, a novel catheter-based device has recently been introduced that specifically interrupts both efferent and afferent renal nerves, and there is significant interest in the use of this device to treat both hypertension and CHF. Several ongoing clinical trials are investigating the safety and efficacy of renal denervation in patients with CHF.
Collapse
|
10
|
|